The online version of this article (doi:10.1007/s00345-015-1722-1) contains supplementary material, which is available to authorized users.
Truls Erik Bjerklund Johansen and Florian Wagenlehner have contributed equally as senior authors.
Primary objective was to identify the (1) relationship of clinical severity of urosepsis with the pathogen spectrum and resistance and (2) appropriateness of using the pathogen spectrum and resistance rates of health-care-associated urinary tract infections (HAUTI) as representative of urosepsis. The secondary objective was to provide an overview of the pathogens and their resistance profile in patients with urosepsis.
A point prevalence study carried out in 70 countries (2003–2013). Population studied included; 408 individuals with microbiologically proven urosepsis, 1606 individuals with microbiological proof of HAUTI and 27,542 individuals hospitalised in urology wards. Main outcomes are pathogens and resistance identified in HAUTIs and urosepsis including its clinical severity. A statistical model that included demographic factors (study year, geographical location, hospital setting) was used for analysis.
Amongst urology practices, the prevalence of microbiologically proven HAUTI and urosepsis was 5.8 and 1.5 %, respectively. Frequent pathogens in urosepsis were E. coli (43 %), Enterococcus spp. (11 %), P. aeruginosa (10 %) and Klebsiella spp. (10 %). Resistance to commonly prescribed antibiotics was high and rates ranged from 8 % (imipenem) to 62 % (aminopenicillin/β lactamase inhibitors); 45 % of Enterobacteriaceae and 21 % of P. aeruginosa were multidrug-resistant. Resistance rates in urosepsis were higher than in other clinical diagnosis of HAUTI (Likelihood ratio <0.05).
It is not appropriate to use the pathogen spectrum and resistance rates of other HAUTIs as representative of urosepsis to decide on empirical treatment of urosepsis. Resistance rates in urosepsis are high, and precautions should be made to avoid further increase.
Supplementary material 1 (PDF 2310 kb)345_2015_1722_MOESM1_ESM.pdf
Johansen TEB, Cek M, Naber K, Stratchounski L, Svendsen MV, Tenke P (2007) Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol 51(4):1100–1111 (discussion 1112) CrossRef
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281 CrossRefPubMed
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101(6):1644–1655 CrossRefPubMed
Grabe M, Bartoletti R, Bjerklund Johansen T-E, Cai T, Cek M, Koves B et al (2013) Guidelines on urological infections 2013, Eur Assoc Urol
Bouza E, Juan RS, Muñoz P, Voss A, Kluytmans J (2001) A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 7(10):523–531
Gordon KA, Jones RN (2003) Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 45(4):295–301 CrossRefPubMed
Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E et al (2014) Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol 32(3):791–801 PubMed
World Health Organization (2014) Antimicrobial resistance: global report on surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed 21 Nov 2015
Antimicrobial resistance surveillance in Europe 2013, European Center for Disease Prevention and Control
Schmid A, Schneider H, Adlof A, Smolle KH, Edelmann G, Sporn P et al (2002) Economic burden of illness imposed by severe sepsis in Austria. Wien Klin Wochenschr 114(15–16):697–701 PubMed
- Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013
Truls Erik Bjerklund Johansen
- Springer Berlin Heidelberg
Neu im Fachgebiet Urologie
Meistgelesene Bücher in der Urologie
Mail Icon II